Recombinant human parathyroid hormone rhPTH (1–84) in patients with hypoparathyroidism. Systematic review [Hormona paratiroidea humana recombinante rhPTH (1–84) en pacientes con hipoparatiroidismo. Revisión sistemática]
DOI:
https://doi.org/10.62574/c9znjd05Keywords:
thyroid hormones, thyroid gland, thyrotropinAbstract
Objective: to study recombinant human parathyroid hormone replacement therapy rhPTH (1–84) in patients with hypoparathyroidism secondary to total thyroidectomy. Method: Systematic review. Results and conclusion: Therapy with recombinant human parathyroid hormone [rhPTH(1-84)] allows mineral homeostasis to be restored in a more physiological way, reducing dependence on calcium and vitamin D supplements and minimising complications associated with conventional treatment, such as nephrocalcinosis and renal deterioration. Likewise, its effectiveness in controlling serum calcium levels and its positive impact on patients' quality of life have been widely supported by scientific evidence.
Downloads
References
Ramacciotti CF, Pereyra MC, Cohen EN. Tratamiento de hipoparatiroidismo con parathormona recombinante humana [rhPTH(1-84)]. Medicina (B Aires). 2020;80(3):289-291.
Ventosa-Viña M, Cuéllar-Olmedo L, Crespo-Soto C, Palacio-Mures JM, García-Duque M, Lázaro-Martín L. Actualización en el tratamiento del hipoparatiroidismo posquirúrgico. Rev ORL. 2022;13(3):e27528. Disponible en: https://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S2444-79862022000400005
Clarke BL, Mannstadt M, Vokes TJ, Rothman J, Warren ML, Denham DS, et al. Three-year safety and efficacy data for recombinant human parathyroid hormone, rhPTH(1-84), in the treatment of adults with hypoparathyroidism: the RACE study. Endocr Abstr. 2015;37. Disponible en: https://www.endocrine-abstracts.org/ea/0037/ea0037OC3.5
Marcucci G, Beccuti G, Carosi G, Cetani F, Cianferotti L, Colao AM, et al. Multicenter retro-prospective observational study on chronic hypoparathyroidism and rhPTH (1–84) treatment. J Endocrinol Invest. 2022;45(9):1653-1662. doi:10.1007/s40618-022-01800-y
Clarke BL, Vokes TJ, Bilezikian JP, Shoback DM, Lagast H, Mannstadt M. Effects of parathyroid hormone rhPTH(1–84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study. Endocrine. 2017;55(1):273-282. doi:10.1007/s12020-016-1141-0
Fuss CT, Burger-Stritt S, Horn S, Koschker AC, Frey K, Meyer A, et al. Tratamiento continuo con rhPTH (1–34) en hipoparatiroidismo crónico. Endocrinol Diabetes Metab Case Rep. 2020;2020. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32478671/
Gamarra E, Retta F, Lucatello B, Ragazzoni F, Camponovo C, Deandrea M, et al. Continuous subcutaneous rhPTH infusion for managing difficult chronic hypoparathyroidism. A systematic review. Endocrine. 2023;81(2):194-205. Disponible en: https://pubmed.ncbi.nlm.nih.gov/37017857/
Liao EP, Cusano NE. Use of rhPTH(1-84) for hypoparathyroidism during early pregnancy and lactation. Endocrinol Diabetes Metab Case Rep. 2023;2023(2). Disponible en: https://pubmed.ncbi.nlm.nih.gov/37335755/
Sosa Henríquez M, Díez Pérez A. La hormona paratiroidea en el tratamiento de la osteoporosis. An Med Interna. 2007;24(2):87-97.
Morán-López JM, Crespo-Gutiérrez J, Puech-de Oriol M. Teriparatida en el tratamiento sustitutivo del hipoparatiroidismo crónico. A propósito de un caso. Rev Osteoporos Metab Miner. 2022;14(4):104-106.
Román-González A, Zea-Lopera J, Londoño-Tabares SA, Builes-Barrera CA, Sanabria A. Pilares para el enfoque y tratamiento adecuado del paciente con hipoparatiroidismo. IATREIA. 2018;31(2):155-165.
Severiche-Bueno DF, Serpa-Serpa CM, Gutiérrez-Morales CV, Rincón-Sierra O. Manejo exitoso de hipoparatiroidismo con PTH(1-34) o teriparatide. Rev Colomb Endocrinol Diabet Metab. 2021;8(1):e697. doi:10.53853/encr.8.1.697
Agarwal S, McMahon DJ, Chen J, et al. The Clinical and Skeletal Effects of Long-Term Therapy of Hypoparathyroidism With rhPTH(1-84). J Bone Miner Res. 2023;38(4):480-492. doi:10.1002/jbmr.4780
Khan AA, Abbott LG, Ahmed I, et al. Open-label extension of a randomized trial investigating safety and efficacy of rhPTH(1-84) in hypoparathyroidism [published correction appears in JBMR Plus. 2024 May 17;8(6):ziae068. doi: 10.1093/jbmrpl/ziae068.]. JBMR Plus. 2024;8(3):ziad010. Published 2024 Jan 5. doi:10.1093/jbmrpl/ziad010
Rejnmark L, Ayodele O, Lax A, Mu F, Swallow E, Gosmanova EO. The risk of chronic kidney disease development in adult patients with chronic hypoparathyroidism treated with rhPTH(1-84): A retrospective cohort study. Clin Endocrinol (Oxf). 2023;98(4):496-504. doi:10.1111/cen.14813
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Emily Valeria Arcos-Aldaz, Natali Mishell Duarte-Cortez, Dennis Alexander Montenegro-Montenegro, Olivia Elizabeth Altamirano-Guerrero
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
CC BY-NC-SA : Esta licencia permite a los reutilizadores distribuir, remezclar, adaptar y construir sobre el material en cualquier medio o formato solo con fines no comerciales, y solo siempre y cuando se dé la atribución al creador. Si remezcla, adapta o construye sobre el material, debe licenciar el material modificado bajo términos idénticos.
